[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638596":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":13,"responsibleParty":30,"collaborators":7,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":7,"eligibilityCriteria":38,"healthyVolunteers":34,"sex":39,"minAge":7,"maxAge":7,"enrollmentInfo":40,"targetDuration":7,"studyType":43,"phases":7,"briefSummary":44,"conditions":45,"keywords":47,"overallStatus":58,"whyStopped":7,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"AgNovos Healthcare, LLC","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DEVICE","AGN1 LOEP","Patients treated with AGN1 LOEP",[14],{"facility":15,"status":7,"city":16,"state":7,"zip":7,"country":17,"countryCode":18,"cosmosGeoPoint":19,"geoPoint":24,"contacts":25},"Vitaz","Sint-Niklaas","Belgium","BE",{"type":20,"coordinates":21},"Point",[22,23],4.1437,51.16509,{"lat":23,"lon":22},[26],{"name":27,"role":28,"phone":7,"phoneExt":7,"email":29},"Jo De Schepper","CONTACT","jo.deschepper@vitaz.be",{"type":31,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100638596","grace-ii-general-retrospective-analysis-of-commercial-experience-with-agn1-loep-100638596",false,"NCT07594639","GRACE II (General Retrospective Analysis of Commercial Experience With AGN1 LOEP)","Retrospective Study of OSSURE LOEP in Osteopenic and Osteoporotic Subjects in the Commercial European Market","Inclusion Criteria:\n\n* Subject has previously received AGN1 LOEP treatment in the proximal femur after September 2019 and before January 2026.\n* Subject can give written informed consent to allow for data collection. Obtaining informed consent is not required for deceased subjects.\n\nExclusion Criteria:\n\n-The subject's AGN1 LOEP treatment was previously performed as part of an AgNovos prior protocoled clinical study.","ALL",{"count":41,"type":42},305,"ESTIMATED","OBSERVATIONAL","The study is designed as a retrospective, multicenter study for subjects previously treated with the AGN1 LOEP Kit in the proximal femur as part of standard hospital practice. This will be a non-randomized and non-blinded study. The study will collect retrospective data on the safety and performance of AGN1 LOEP of all subjects treated between September 2019 and January 2026. Subjects treated as part of an AgNovos prior protocoled study are excluded. Investigators are asked to reach out to all subjects that were previously treated with the AGN1 LOEP Kit in the proximal femur. Subject informed consent is obtained before a subject is enrolled into the study. Subjects treated but not enrolled are documented in a log with the reason why a subject did not participate. This log is kept on site. Enrolled subjects will be contacted per telephone to collect information about any fractures sustained post-AGN1 LOEP treatment.",[46],"Osteoporosis",[48,49,50,51,52,53,54,55,56,57],"Bone mineral density","Femoral strength","Hip fracture","Local osteo-enhancement procedure","LOEP","Proximal femur","Osteogenesis Imperfecta","OI","Hypophosphatasia","HPP","NOT_YET_RECRUITING","2026-05-15",{"date":61,"type":62},"2026-05-19","ACTUAL",{"date":64,"type":42},"2026-06-01",{"date":66,"type":42},"2026-09-30",{"name":5,"class":6},1]